Emiel De Jaeghere

Emiel De Jaeghere
Ghent University | UGhent · Medical Oncology

MD

About

22
Publications
1,592
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
189
Citations
Introduction
Emiel De Jaeghere, MD, is a resident and PhD student at the Department of Medical Oncology of Ghent University Hospital and the Laboratory for Experimental Cancer Research (Ghent, Belgium). His areas of interest are immuno-oncology and the treatment of tumors of the female reproductive system.
Education
October 2014 - June 2018
Ghent University
Field of study
  • Medicine
October 2011 - June 2014
Ghent University
Field of study
  • Medicine

Publications

Publications (22)
Article
Full-text available
A phase II study (PRIMMO) of patients with pretreated persistent/recurrent/metastatic cervical or endometrial cancer is presented. Patients received an immunomodulatory five-drug cocktail (IDC) consisting of low-dose cyclophosphamide, aspirin, lansoprazole, vitamin D, and curcumin starting 2 weeks before radioimmunotherapy. Pembrolizumab was admini...
Article
Full-text available
Purpose: This longitudinal survey study aimed to investigate the self-reported outcome measures of COVID-19 peritraumatic distress, depression, anxiety, stress, quality of life (QOL), and their associated factors in a cohort of cancer patients treated at a tertiary care hospital during the SARS-CoV-2 pandemic. Methods: Surveys were administered...
Article
Full-text available
The current study aimed to investigate the impact of the COVID-19 pandemic on the mental health of people with OCD and the degree of family accommodation (FA) by live-in family members across phases of the lockdown measures imposed by the Belgian government. Forty-nine OCD patients and 26 live-in family members participated in the study. We assesse...
Article
Full-text available
Thromboembolic events are the second cause of death in cancer patients. In ovarian cancer, 3–10% of patients present with venous thromboembolism (VTE), but the incidence may rise to 36% along the disease course. Bevacizumab is a monoclonal antibody directed against vascular endothelial-derived growth factor, and in in vitro studies it showed a pred...
Article
Tumor-derived secretory factors orchestrate splenic hematopoietic and stromal cells to fuel metastasis. The spleen acts as a reservoir site for hematopoietic stem and progenitor cells, which are rapidly exploited as myeloid-derived suppressor cells at the cost of tumor-reactive lymphoid cells. Splenic erythroid progenitor cells and mesenchymal stro...
Article
Objective The spleen represents an important contributor to tumor immune escape, but the relevance of increased splenic metabolic activity remains to be fully elucidated. Methods We retrospectively measured the spleen-to-liver standard uptake value (SLR) on ¹⁸F-FDG PET/CT examinations of 92 consecutive patients with FIGO stage IB1 to IVA cervical...
Article
We investigated the potential of tumor-infiltrating immune cells as predictive or prognostic biomarkers for cervical cancer patients. In total, 38 patients treated with (chemo)radiotherapy and subsequent surgery were included in the current study. This unique treatment schedule makes it possible to analyze immune cell markers in pre- and post-treat...
Article
Full-text available
Since tobacco remains a leading cause of global morbidity and mortality, emphasis needs to be given to preventive approaches to tobacco consumption. Environmental and policy strategies with fear appeals are important contributors to reductions in smoking prevalence. Fear appeals are persuasive messages-often using graphic and emotionally evocative...
Article
Immune escape is central to the persistence of most, if not all, solid tumors and poses a critical obstacle to successful cancer (immuno)therapy. Cancer-associated fibroblasts (CAFs) constitute the most prevalent, yet heterogeneous, component of the tumor stroma, where they 'cool down' the immune microenvironment. The central role played by CAFs, b...
Conference Paper
Introduction/Background We investigated the potential of tumour-infiltrating immune cells in pre- and post-treatment tissue specimens and their changes during treatment as predictive or prognostic biomarkers for cervical cancer patients. Methodology Cervical cancer patients treated with (chemo)radiotherapy and subsequent surgery were included in t...
Conference Paper
Background Inflammation has a significant impact on cervical cancer (CC) development and therapy response. We sought to determine if splenic metabolic activity reflects host immune status and could improve prognostic and predictive categorization of CC. Methods Ninety-two consecutive patients with FIGO stage IB1 to IVB CC who received neo-adjuvant...
Article
Full-text available
Background Immunotherapeutic approaches have revolutionized oncological practice but are less evaluated in gynecological malignancies. PD-1/PD-L1 blockade in gynecological cancers showed objective responses in 13–17% of patients. This could be due to immunosuppressive effects exerted by gynecological tumors on the microenvironment and an altered tu...
Article
Full-text available
Background: Previous studies on cervical cancer reported a worse outcome for adenocarcinoma (AC) compared with squamous cell carcinoma (SCC). Nevertheless, standard treatment remains identical. Insight in the impact of histological types on biological behavior and pathological complete response rates might result in a treatment paradigm shift. Meth...
Article
Peritoneal metastases cause cancer mortality and preclinical models are urgently needed to boost therapeutic progress. This study reports on a hybrid hydrogel-polylactic acid (PLA) scaffold that mimics the architecture of peritoneal metastases at the qualitative, quantitative and spatial level. Porous PLA scaffolds with controllable pore size, shap...
Article
Peritoneal metastasis is a major cause of death and preclinical models are urgently needed to enhance therapeutic progress. This study reports on a hybrid hydrogel-polylactic acid (PLA) scaffold that mimics the architecture of peritoneal metastases at the qualitative, quantitative and spatial level. Porous PLA scaffolds with controllable pore size,...
Article
Full-text available
Intraperitoneal (IP) drug delivery, either as an intraoperative chemoperfusion or as adjuvant, repeated instillation, is an established treatment modality in patients with peritoneal carcinomatosis. The efficacy of IP drugs depends on its ability to penetrate the tumor stroma in order to reach their (sub)cellular target. It is known, that drug pene...
Article
DNA repair mechanisms play a key role in oncogenesis and cancer progression in women with BRCA mutation-positive (BRCAm) ovarian cancer (OC). The BRCA1/2 and poly(ADP-ribose) polymerase (PARP) proteins are considered the foremost mediators among the various components of double-strand and single-strand repair, respectively. A series of new therapeu...

Network

Cited By

Projects

Projects (2)
Project
Definitive chemoradiotherapy (CRT) is considered standard of care in locally advanced cervical cancer (LACC). Definitive CRT is a 2-step process consisting of external beam radiotherapy ± chemotherapy and a brachytherapeutic (BT) boost. Even with the use of image-guided dose-intensified BT, local relapse arising from CRT-resistant foci is high (3y-local pelvic control rates of 73% up to 96%, depending on stage and treating center) and remains a major cause of treatment failure. Triggered off by both the high local recurrence and the toxicity rates we challenged the gold standard by introducing intensity-modulated arc therapy (IMAT) followed by C1 radical hysterectomy (HRT).
Project
Application of biomimetic scaffolds for tissue engineering of the peritoneal metastatic niche, in particular for optimization of intraperitoneal drug delivery.